Pfizer cuts full-year outlook due to declining sales of Covid-19-related products

Indonesia Berita Berita

Pfizer cuts full-year outlook due to declining sales of Covid-19-related products
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 AP
  • ⏱ Reading Time:
  • 35 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 51%

Shares of Pfizer are falling before the opening bell as the company cut its full-year outlook, citing declining sales of its COVID-19-related products. Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion. Its prior forecast was for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.

FILE - The Pfizer logo is displayed at the company’s headquarters, Friday, Feb. 5, 2021, in New York. Shares of Pfizer are falling before the market opened on Monday, Oct. 16, 2023, as the company cut its full-year outlook, citing declining sales of its COVID-19-related products.

The company said Friday that global usage of Paxlovid is trending slightly above last year, but that it’s still below expectations.Booking a COVID-19 vaccine? Some are reporting canceled appointments or insurance issues Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected.

Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

AP /  🏆 728. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Pfizer, BioNTech shares fall on lower COVID product sales forecastPfizer, BioNTech shares fall on lower COVID product sales forecastShares of Pfizer (PFE.N) and German partner BioNTech (22UAy.DE) fell on Monday after the U.S. drugmaker slashed the sales forecast for its COVID vaccine and therapy last week, and some analysts said the reduction was bigger than expectations.
Baca lebih lajut »

Pfizer slumps after slashing full-year profit forecast on tumbling Covid salesPfizer said slumping demand for its Comirnaty covid vaccine and its Paxlovid antiviral treatment will mean sharply lower revenues for the full year.
Baca lebih lajut »

COVID Map Shows States With Highest Positive TestsCOVID Map Shows States With Highest Positive TestsColorado, Montana, North Dakota, South Dakota, Utah, and Wyoming had the highest positivity rate in the nation at 13.4 percent.
Baca lebih lajut »

Why Experts Say You Shouldn’t Run With COVID-19Why Experts Say You Shouldn’t Run With COVID-19Donna Raskin has had a long career as a health and fitness writer and editor of books and magazine articles. She bikes in a nearby county park, lifts weights, takes Zumba, and loves to walk/run with her dog, Dolly.
Baca lebih lajut »

Biden Allocates $33.7M COVID-19 Relief to Palestinian GroupIn a move drawing both support and criticism, the Biden administration has allocated $33.7 million from the American Rescue Plan to the United Nations Relief and Works Agency, a Palestinian relief organization.
Baca lebih lajut »

Ban on COVID vaccine mandates by private businesses, including health care facilities, passes Texas SenateBan on COVID vaccine mandates by private businesses, including health care facilities, passes Texas SenateA sweeping ban on COVID-19 vaccine mandates for employees of private Texas businesses passed the Texas Senate early Friday, although medical facilities would be
Baca lebih lajut »



Render Time: 2025-02-28 09:19:13